Newsroom

Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM

December 9, 2024

December 9, 2024

Videoconference and publication of half-year financial results, Tuesday, December 10, 2024

November 29, 2024

November 29, 2024

25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI clinical Phase 3

November 6, 2024

November 6, 2024

New Phase 3 Positive Results for Olanzapine LAI and Real-World Data on UZEDY®

November 4, 2024

November 4, 2024

Participation in Leading Investor Conferences

October 28, 2024

October 28, 2024

Ultrasensitive In Vitro and Ex Vivo Tracking of 13C-Labeled PEG–PLA Degradation Products by MALDI-TOF Mass Spectrometry

October 23, 2024

October 23, 2024

Revisiting the nature and pharmacodynamics of tacrolimus metabolites

September 27, 2024

September 27, 2024

New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI

September 23, 2024

September 23, 2024

New Treatment Insights into Switching to UZEDY® from Perseris®

September 23, 2024

September 23, 2024

2024 Annual General Meeting (French)

September 13, 2024

Reporting of the 2024 Annual General Meeting

September 13, 2024

September 13, 2024

Presentation at the H.C. Wainwright 26th Annual Global Investment Conference (New York, September 9 to 11)

September 5, 2024

September 5, 2024